Pure Global AI
NCT06260267Not yet recruiting

A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

Ferring PharmaceuticalsPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Ulcerative Colitis
Drug/Device/Intervention
Microbiota suspension
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ferring Pharmaceuticals
Timeline & enrollment
Phase
Phase 1
Start date
Mar 20, 2024
End date
Sep 15, 2025
Enrollment
90 participants
Primary outcome

Treatment-emergent adverse events from baseline to week 52

Summary

To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule)
 versus placebo in subjects with active mild to moderate ulcerative colitis (UC).

ICD-10 classifications
Ulcerative colitisOther ulcerative colitisUlcerative colitis, unspecifiedArthropathy in ulcerative colitisJuvenile arthritis in ulcerative colitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06260267
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06260267 through Pure Global AI's free database. This Phase 1 trial is sponsored by Ferring Pharmaceuticals and is currently Not yet recruiting. The study focuses on Ulcerative Colitis. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.